Table 2.

Characteristics of glioma subjects, San Francisco Bay Area Adult Glioma Study, 1991-2000

All glioma *GlioblastomaAnaplastic astrocytoma
All case subjects
    No.873519105
    Mean age (SE)55.4 (0.6)61.6 (0.6)51.1 (1.5)
    % Male56.456.352.4
    % White82.884.076.2
    Median mos survival (95% CL)11.0 (10.0-12.5)7.1 (6.5-7.8)13.0 (9.9-19.5)
Subjects with any genotyping or serologic data
    No.47123057
    Mean age (SE)50.8 (0.7)57.6 (0.8)47.4 (1.8)
    % Male59.263.050.9
    % White83.083.580.7
    Median mos survival (95% CL)19.7 (17.7-22.7)12.4 (10.8-13.7)20.7 (18.5-41.6)
All cases with astrocytic tumors
    No.667
    Mean age (SE)58.8 (0.6)
    % Male55.6
    % White82.3
    Median mos survival (95% CL)8.0 (7.3-9.0)
Astrocytic subjects with any tumor marker data
    No.59545288
    Mean age (SE)58.7 (0.6)61.8 (0.6)51.4 (1.7)
    % Male58.057.758.0
    % White84.285.478.4
    Median mos survival (95% CL)8.6 (7.7-9.6)7.2 (6.7-8.0)14.6 (10.6-20.6)
  • NOTE: Median months survival and 95% CLs estimated with Kaplan-Meier methods.

  • Abbreviations: SE, Standard Error; 95% CL, 95% Confidence Limit.

  • * Numbers of subjects with other histologies were astrocytoma grade 2 (n = 43), anaplastic oligodendroglioma (n = 26), anaplastic oligoastrocytoma (n = 16), oligodendroglioma (n = 67), oligoastrocytoma (n = 40), ependymoma (n = 8), juvenile pilocytic astrocytoma (n = 15), medulloblastoma (n = 10), and others (n = 24).